Discussion  by unknown
References
1. Cheng DC, Bainbridge D, Martin JE, Novick RJ. Evidence based perioperative
clinical outcomes research group. Does off-pump coronary artery bypass reduce
mortality, morbidity, and resource utilization when compared with conventional
coronary artery bypass? A meta-analysis of randomized trials. Anesthesiology.
2005;102:188-203.
2. Wijeysundera DN, Beattie WS, Djaiani G, Rao V, Borger MA, Karkouti K, et al.
Off pump coronary artery surgery for reducing mortality and morbidity: meta-anal-
ysis of randomized and observational studies. J AmColl Cardiol. 2005;46:872-82.
3. Ascione R, Lloyd CT, Underwood MJ, Lotto AA, Pitsis AA, Angelini GD.
Economic outcome of off-pump coronary artery bypass surgery: a prospective
randomized study. Ann Thorac Surg. 1999;68:2237-42.
4. Puskas JD, Williams WH, Mahoney EM, Huber PR, Block PC, Duke PG, et al.
Off-pump vs. conventional coronary artery bypass grafting: early and 1-year graft
patency, cost, and quality-of-life outcomes: a randomized trial. JAMA. 2004;291:
1841-9.
5. Nathoe HM, van Dijk D, Jansen EWL, Suyker WJ, Diephuis JC, van Boven WJ,
et al. A comparison of on-pump and off-pump coronary bypass surgery in low-
risk patients. N Engl J Med. 2003;348:394-402.
6. Cleveland JC Jr, Shroyer AL, Chen AY, Peterson E, Grover FL. Off-pump coro-
nary artery bypass grafting decreases risk-adjusted mortality and morbidity. Ann
Thorac Surg. 2001;72:1282-8.
7. Keogh BE, Kinsman R. Fifth National Adult Cardiac Surgical Database report for
2003. Henley-on-Thames, United Kingdom: Dendrite Clinical Systems; 2004.
8. Lim E, Drain A, Davies W, Edmonds L, Rosengard BR. A systematic review of
randomized trials comparing revascularization rate and graft patency of off-pump
and conventional coronary surgery. J Thorac Cardiovasc Surg. 2006;132:
1409-13.
9. Angelini GD, Taylor FC, Reeves BC, Ascione R. Early and midterm outcome af-
ter off-pump and on-pump surgery in Beating Heart Against Cardioplegic Arrest
Studies (BHACAS 1 and 2): a pooled analysis of two randomised controlled trials.
Lancet. 2002;359:1194-9.
10. Ascione R, Reeves BC, Taylor FC, Seehra HK, Angelini GD. Beating Heart
Against Cardioplegic Arrest Studies (BHACAS 1 and 2): quality of life at
mid-term follow-up in two randomised controlled trials. Eur Heart J. 2004;
25:765-70.
11. Schlosser T, Konorza T, Hunold P, Ku¨hl H, Schmermund A, Barkhausen J. Non-
invasive visualization of coronary artery bypass grafts using 16-detector row com-
puted tomography. J Am Coll Cardiol. 2004;44:1224-9.
12. Ascione R, Caputo M, Calori G, Lloyd CT, Underwood MJ, Angelini GD. Predic-
tors of atrial fibrillation after conventional and beating heart coronary surgery:
a prospective randomised study. Circulation. 2000;102:1530-5.
13. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, et al. A re-
porting system on patients evaluated for coronary artery disease. Report of the Ad
Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovas-
cular Surgery, American Heart Association. Circulation. 1975;51(suppl):5-40.
14. Taylor FC, Reeves BC, Ascione R, Angelini GD. Accuracy of reporting cardiac
related events during long-term follow-up. Heart. 2003;89:331-2.
15. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, et al.
Development and evaluation of the Seattle Angina Questionnaire: A new func-
tional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25:
333-41.
16. Schroter S, Lamping DL. Coronary revascularisation outcome questionnaire
(CROQ): development and validation of a new, patient based measure of outcome
in coronary bypass surgery and angioplasty. Heart. 2004;90:1460-6.
17. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36):
I. Conceptual framework and item selection. Med Care. 1992;30:473-83.
18. Ware JE, Kosinski M, Gandek B. SF-36 Health Survey. Manual and interpretation
guide. Lincoln, RI: QualityMetric Incorporated; 2000.
19. EuroQol Group. EuroQol—a new facility for the measurement of health-related
quality of life. Health Policy. 1990;16:119-208.
20. Widimsky P, Straka Z, Stros P, Jirasek K, Dvorak J, Votava J, et al. One-year
coronary bypass graft patency: a randomized comparison between off-pump
and on-pump surgery angiographic results of the PRAGUE-4 trial. Circulation.
2004;110:3418-23.
21. Khan NE, De Souza A, Mister R, Flather M, Clague J, Davies S, et al. A random-
ized comparison of off-pump and on-pump multivessel coronary-artery bypass
surgery. N Engl J Med. 2004;350:21-8.
22. Van Dijk D, Jansen EW, Hijman R, Nierich AP, Diephuis JC, Moons KG, et al.
Cognitive outcome after off-pump and on-pump coronary artery bypass graft sur-
gery: a randomized trial. JAMA. 2002;287:1405-12.
23. Watters MPR, Ascione R, Ryder IG, Ciulli F, Pitsis AA, Angelini GD. Haemody-
namic changes during beating heart coronary surgery with the ‘‘Bristol tech-
nique.’’ Eur J Cardiothorac Surg. 2001;19:34-40.
Acquired Cardiovascular Disease Angelini et al




Dr Soichiro Kitamura (Osaka, Japan). I thank the Association
for the privilege of discussing this fine article. I also thank Professor
Angelini for allowing me to read the manuscript before the presen-
tation. My compliments on a well—designed and well—conducted
clinical study demonstrating again that OPCAB can offer good
quality of surgical intervention in terms of 6 to 8 years’ graft pa-
tency, survival and survival free from MACEs, and patients’
HRQoL after surgical intervention in comparison with conven-
tional on—pump CABG.
This article is certainly the extension of a previously published
randomized clinical trial called the BHACAS 1 and 2 conducted
almost 10 years ago, and today, the chief researchers again demon-
strated that OPCAB, as compared with on-pump CABG, can yield
a similar level of long-term survival and quality of life based on
the similar long-term graft patency evaluated by using 16-array
MDCTA.
Your group reported in 2002 and 2004 that OPCAB provided
significant reduction in postoperative morbidity compared with
that seen after conventional on-pump CABG, such as a 25% reduc-
tion in postoperative atrial fibrillation, a 31% reduction in blood
transfusion, fewer chest infections, shorter intensive care unit
stay, and so on. Also, a midterm follow-up study showed that ran-
domized patients had a similar generic and disease-specific quality
of life. However, OPCAB remains in only 15% to 20% of total
practice in Western countries, you said.
On the contrary, in Japan surgeons have adopted this technique
for about 60% of patients undergoing isolated CABG, and in my
institution, the National Cardiovascular Center, 98% of isolated
CABG procedures have been performed using the OPCAB tech-
nique, probably because in Japan angiographic follow-up is rather
routine, which can allow surgeons and cardiologists to evaluate and
confirm their own results. Very interestingly, once surgeons are
trained and accustomed to do it, they are reluctant to go back to
on-pump CABG because they are more comfortable with this tech-
nique because of easy hemostasis and easy adjustment of the graft
length for complicated graft arrangement. I believe the basic reason
for this technology not being popularized well, regardless of less
use of resources and reduction of early postoperative morbidity,
is the surgeons’ attitude anesthesiologists’ attitude, or both and
the training system.
My first question is this: Why has reduction in postoperative
morbidity contributed very little to the wide application of this tech-
nique? You mentioned that this was probably because of the con-
cern about long-term graft patency and clinical results. What
would you think about the importance of a training system, change
of attitude, or both for OPCAB rather than evidence demonstrated
by a handful of surgeons who are used to doing it?
Dr Angelini. Thank you, Dr Kitamura, for your kind remarks
and your very appropriate question, which is not easy to answer.
I have visited Japan on many occasions, and I have always been
surprised by the skill and level with which you have adopted OP-
CAB surgery and also arterial revascularization, 2 techniques that
are very poorly used in the Western world.ery c February 2009
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DI think we have plenty of evidence on the benefits of OPCAB
surgery. To say, as I heard this morning, that a reduction in blood
loss is not such important evidence is a very feeble excuse. I think
this is a technique that requires an institution’s commitment to it
and not just the surgeon and anesthetist but the whole team, and
you have to be prepared to go through a learning process, which
can be painful. Perhaps this is one of the reasons why surgeons
are not prepared to adopt OPCAB surgery.
Maybe there is another explanation. I was reading an editorial
written 5 or 6 years ago by Lawrence Bonchek, a very well-known,
now retired, American surgeon, who asked, ‘‘Is off-pump for ev-
erybody?’’ After all, not all of us can perform mitral valve repair,
extensive arterial revascularization, or aortic valve sparing. There-
fore perhaps we should see the off-pump procedure as a specialized
procedure and to think that everybody will be able to adopt it is per-
haps just not feasible.
Dr Kitamura. Well, if I am correct, you are planning to con-
duct a new randomized trial of OPCAB versus CABG–CPB in
patients with poor left ventricular function. Conversion from
OPCAB to on-pump CABG in a hasty situation has been re-
ported to result in high mortality. Urgent conversion occursThe Journal of Thoracic and Camore often in patients with poor and large left ventricles. At
present, would you think OPCAB should be limited for the pa-
tients with a low probability of conversion until new evidence
comes out?
Dr Angelini. Thank you, again, for this question. We are indeed
going to carry out a large study supported by the Medical Research
Council in the United Kingdom. The plan is to enroll 5000 patients
(EuroSCORE>5). Therefore these will be patients with poor ven-
tricular function but also redo operations, patients with renal im-
pairment, lung dysfunction, and so forth.
As far as conversion is concerned, our experience was reported
about 2 years ago in the European Journal of Cardio-Thoracic Sur-
gery; for the period 1995 to 2005, we had an overall conversion of
1.1%, going from 5.2% in the 1995 to 1996 period to less than 0.4%
in the most recent years. I think in institutions in which OPCAB
surgery has been adopted, after a proper learning curve, the risk
of conversion is very small.
DrKitamura. I once again congratulate you and your associates
on this excellent clinical research, and I hope this evidence can sig-
nificantly contribute to the prevalence of the OPCAB technique.
Thank you very much.rdiovascular Surgery c Volume 137, Number 2 303
